September 21, 2021 -- InvestorsHub NewsWire -- via NetworkNewsWire
Editorial Coverage: Exorbitant costs underscored by byzantine
processes plague today’s healthcare systems, creating
an $8.45
trillion global healthcare market in 2018, which
represents about 10% of GDP in developed countries. Safe to say,
the industry is looking for solutions, particularly more efficient
ones that improve health outcomes and lower direct and indirect
costs. The answer is found in technology, with healthtech
(healthcare technology) and medtech (medical technology) buzzwords
speaking to leveraging next-generation innovation in a bid to
flatten the healthcare spending curve. New applications are being
launched daily, and uptake is accelerating, fanned by the COVID-19
pandemic that bolstered adoption of self-diagnostic and remote
solutions that have been embraced by health insurers and
individuals alike. Some companies, such as Nemaura
Medical Inc. (NASDAQ:
NMRD) (Profile), are specializing in certain areas
of unmet medical need, such as diabetes and obesity for NMRD.
Others, including some of the most recognized names in the world
such as Tesla Inc. (NASDAQ:
TSLA), Apple Inc. (NASDAQ:
AAPL), Garmin Ltd. (NASDAQ:
GRMN) and Amazon.com Inc. (NASDAQ:
AMZN), demonstrate the tremendous opportunity at hand
for investments in new technologies and healthtech.
- UNC study showed only 12% of participants achieve optimal
metabolic health, increasing risk for diabetes, heart disease and
stroke.
- Nemaura Medical’s BEAT(R) diabetes platform represents
affordable innovation to treat, reverse diabetes and obesity.
- Nemaura already has contract for 200,000 units and a rolling
contract forecast to include 2 million sensors over 24 months.
- Technology is scalable into other markets, including monitoring
body temperature, lactate, and alcohol and drug ingestion
Click here to view the custom infographic of
the Nemaura Medical Inc. editorial.
Can Tech Reverse a Trend in Poor Metabolic
Health?
While there is no official calculation of metabolic health, its
importance in quality of life is well known. Most experts assess
five key health markers: medicine-free readings of blood glucose,
triglycerides, cholesterol, blood pressure and waist circumference.
The poignant conclusion of a seven-year study by University of North Carolina researchers
was that a meager 12% of Americans achieve optimal metabolic
health, which increases risk for diabetes, heart disease, stroke
and associated comorbidities of those. Obese patients performed the
worst, with only 0.5% of individuals in this group achieving
optimal metabolic health.
The rise in obesity, recognized as a body mass index over 30, is
leading an upward trend in diagnoses of diabetes and prediabetes,
which are characterized and defined by poor glucose control.
Diabetes, which by all estimates can be mostly preventable, is a
deep concern considering 10.5% of all
Americans — and 13% of adults — have the disease. A
stunning 34.5% of Americans are prediabetic.
Globally, 463 million people have diabetes. Data from the World
Health Organization shows that diabetes kills about 3.4 million
people worldwide each year. The actual number of deaths where
diabetes is the culprit can be difficult to discern because
diabetics typically grow progressively more ill, with high blood
sugar damaging the heart, blood vessels, kidneys, eyes and
nerves.
Nemaura Medical Inc.
(NASDAQ:
NMRD) has spent the last decade developing the
world’s first daily-wear, noninvasive glucose sensor and integrated
healthcare app. The company’s BEAT(R) diabetes platform, inclusive
of sugarBEAT(R) CGM and proBEAT(TM), which combines noninvasive
glucose data processed using artificial intelligence (“AI”) and a
digital healthcare subscription service, are clearly differentiated
from others in form and function. The platform uses an integrated
approach that empowers individuals to lose weight and reverse
diabetes or prediabetes. Furthermore, Nemaura combines an
integrated app with proprietary intellectual property that is
protected by more than 30 patents (approved or pending), a
metabolic health program that provides an edge over similar options
such as NOOM, etc.
The design of the platform affords Nemaura the opportunity to
diversify into different markets, both horizontal and vertical. The
company is already seeing success overseas as evidenced by a soft
launch of the CE-approved medical device in the United Kingdom as
well as interest from other potential partners in Europe and Middle
East, both regions where diabetes and obesity are rampant. Further,
the system can be tweaked to address the complete metabolic health
spectrum and other markets, including monitoring body temperature,
lactate, and alcohol and drug ingestion. In combination with
predictive technologies such as AI and machine learning, the future
for the platform is a blue sky.
BEAT-ing Diabetes in a New Way
Continuous glucose monitoring (“CGM”) isn’t new, but the
innovation of Nemaura is to develop a robust system complete with
mass-market sugarBEAT CGM sensors, analytics, personalized coaching
and a metabolic health app. The company overcomes the obstacle of
intrusiveness with its novel sensors. Today, competing sensors are
mostly invasive and involve inserting a one-centimeter-long
filament in the arm, which remains in place for 10 to 14 days.
Not with Nemaura. Its proprietary sensors don’t penetrate the
skin at all, instead sitting atop the surface of the skin much like
a Band-Aid. Nor do the sensors require extended wear periods.
People suffering from diabetes, prediabetes or obesity typically
only need to wear a sensor for a few days each month, and the
individual dictates the time and day, disposing of the sensor
daily. Fewer sensors used for fewer days means lower costs of
disease management.
The data is transmitted from the sensor in real time every five
minutes, and glucose profiles only need to be obtained at the end
of each month to keep in check. In the WhyWait program, patients
received guidance for diet and exercise adjustments based on
self-monitored blood glucose (“SMBG”). The weight-loss program was
originally developed at the Joslin Diabetes Centre, undergirded by
more than 12 years of clinical evidence that was subsequently
replicated using a virtual program showing durable weight loss
without loss of muscle mass. This has now been incorporated in to
Nemaura’s BEATdiabetes program.
Flipping the Script to Time in Range
For decades, the benchmark for diabetes management has been
HbA1C, a measure of the amount of blood sugar attached to
hemoglobin, which is in red blood cells and carries oxygen from
lungs throughout the body. The problem is that non-CGM collected
HbA1C levels are averages that can give the same result while
varying greatly throughout any given period. Think of it as a math
equation. The ways “7” can be achieved are infinite (i.e., 5+2,
9-2, 11-4, 1+6, etc.).
A critical advantage of a CGM-based system such as the one
offered by Nemaura is the ability to measure the time glucose
levels are in a normal range, or time in range (“TIR”). For HbA1C,
this can be defined as anywhere between 3.9 and 10.0 millimoles per
liter (mmol/l). Knowing when and how much a person’s blood sugar is
outside that target range can be instrumental in disease
management. In short, understanding and controlling TIR leads to
reducing the onset of complications of diabetes.
Orders for 200,000 Sensors and Counting
Nemaura expects that its technology can lead to meaningful
improvements in HbA1C, blood cholesterol, blood pressure and
sustainable weight loss — at an affordable price. Given that
each case of diabetes costs employers and insurers more than $9,000
per year on average, compared to only $1,200 for nondiabetic
individuals, subscription costs (and then some) can be recouped
through avoidance of healthcare interventions and increased
employee productivity.
NMRD’s BEAT diabetes platform has recently been launched in the
United States with a PMA filed with the FDA. A soft launch in the
United Kingdom resulted in purchase orders for 200,000 sensors and
rolling POs forecast for 2 million sensors in the next 24 months.
Nemaura is reportedly in negotiations with several third parties
internationally regarding its sugarBEAT and BEAT platforms.
Wall Street Loves Tech
Diabetes and obesity are relatively quiet topics in the
investment media, which is somewhat surprising considering the
incredible size of their addressable markets, totaling some 1.5
billion people currently and rising. Granted, the diseases have
been notoriously difficult to treat, but there is optimism that
technology will change the landscape, a fact that was made clear
with the $18.5 billion acquisition of digital health upstart Livongo in
2020, mainly for its consumer-facing diabetes app. Tech appears to
be hot and is likely going to stay that way.
Tesla Inc. (NASDAQ:
TSLA) is a great example of growth and investor
appetite for companies bringing new tech to market. Making its
first all-electric Roadster in 2008, investors jumped
into the
company when it went public in 2010, trading in single
dollar digits and barely delivering any cars each quarter. In 2016,
deliveries still averaged under 19,000 per quarter. Growth has
abounded and so have deliveries since, with the stock soaring over
$900 per share and deliveries topping 201,000 during Q2 2021.
Apple Inc. (NASDAQ:
AAPL) is the 700-pound gorilla of technology. The
stock has been in an uptrend for 20 years as consumers and
investors look to the brand. On Sept. 14, 2021, Apple unveiled the latest iteration of its
iPhones, the iPhone 13 Pro and Pro Max, with the most advanced
camera system ever on IPhone, Super Retina XDR display with
ProMotion, massive leap in battery life, fastest chip yet and more.
In addition, Apple is advancing its position in the healthcare and
fitness spaces with its technology, including reports for future Apple watches to include
temperature and blood glucose sensors.
Garmin Ltd. (NASDAQ:
GRMN) is a key player in the wearable technology
space. In addition to is latest technology for boats and
airplanes, Garmin has announced its Surfline widget that
allows surfers to check conditions for the five nearest surfing
spots from a paired compatible Garmin smartwatch, along with its
new Adventure Racing sport profile, a new activity profile that
allows participants to track vital information and utilize their
Enduro(TM) ultraperformance multisport watch while adhering to the
rules and regulations of Adventure Racing competitions, making it
the first GPS-enabled watch that is Adventure Race authorized.
Amazon.com Inc. (NASDAQ:
AMZN) is a newer entrant in the healthcare
segment, a signal of the tremendous growth potential of the space.
The ecommerce behemoth has diversified in multiple directions,
including now operating Amazon Care, a virtual-visit service
trumpeting no appointments and no waiting rooms for nonemergency
conditions seven days a week and 365 days a year. Amazon,
through its Web Services unit, has also launched a healthcare
accelerator business to bolster startups’ growth and incubate
early-stage digital health companies.
Healthcare is at an inflection point. The movement was already
coming about through a need for innovation, but it gained tailwinds
because of even more need to deal with the COVID-19 economy.
Technology never turns back once it evolves. In many cases, such as
with hard-to-treat, prominent diseases that are a serious drain on
healthcare systems, tech is re-shaping the paradigm and bring new
solutions for the good of all involved.
For more information about Nemaura Medical Inc., please
visit Nemaura
Medical Inc. (NASDAQ:
NMRD).
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a financial news and
content distribution company, one of 50+ brands within
the InvestorBrandNetwork (“IBN”), that
provides: (1) access to a network of wire
solutions via InvestorWire to reach all target markets,
industries and demographics in the most effective manner
possible; (2) article and editorial
syndication to 5,000+ news outlets; (3)
enhanced press release solutions to ensure maximum
impact; (4) social media distribution via IBN
millions of social media followers; and (5) a
full array of corporate communications solutions. As a multifaceted
organization with an extensive team of contributing journalists and
writers, NNW is uniquely positioned to best serve private and
public companies that desire to reach a wide audience comprising
investors, consumers, journalists and the general public. By
cutting through the overload of information in today’s market, NNW
brings its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text
“STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable NNW for any investment
decisions by their readers or subscribers. NNW is a news
dissemination and financial marketing solutions provider and are
NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, NNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and NNW undertakes no
obligation to update such statements.
SOURCE: NetworkNewsWire
Editorial Coverage
Garmin (NASDAQ:GRMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Garmin (NASDAQ:GRMN)
Historical Stock Chart
From Apr 2023 to Apr 2024